Abstract
Biological products represent a growing segment of the pharmaceutical industry. Stability studies of these complex biologics present challenges beyond those found for the typical small-molecule pharmaceutical. Biologic products are typically only marginally stable, not entirely understood, may demonstrate non-Arrhenius behavior, degrade by multiple pathways and possibly different pathways during different stages of shelf life. Further, subtle changes brought on by stresses can have large effects on the therapeutic properties of the product. There are analytical methodology challenges pertaining to monitoring stability as well, in particular the higher variance and complexity of the product and methodology. The issues and strategies involved in studying the stability of biologic protein products, particularly for the purposes of product registration purposes are discussed as well as an overview of ICH Q5C Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products. Stability protocols should be designed keeping in mind the idiosyncrasies of biologics as well as formulation, analytical, manufacturing, and regulatory knowledge gained during development.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Mikkelsen SR, Cortòn E (2004) Bioanalytical Chemistry. Wiley Interscience, Hoboken.
Jacob S, Shirwaikar AA, Srinivasan KK, Alex J, Prabu SL, Mahalaxmi R, Kumar R (2006) Stability of proteins in aqueous solution and solid state. Indian J Pharm Sci 68(2):154–163.
Chan H, Dill K (1998) Protein folding in the landscape perspective: chevron plots and non-arrhenius kinetics. Proteins: Struct Funct Genet 30:2–33.
Collet O, Chipot C (2003) Non-arrhenius behavior the unfolding of a short hydrophobic upalpha-helix. complementarity of molecular dynamics and lattice model simulations. J Am Chem Soc 125:6573–6580.
Roberts CJ, Darrington RT, Whitley MB (2003) Irreversible aggregation of recombinant bovine granulocyte-colony stimulating factor (bG-CSF) and implications for predicting protein shelf life. J Pharm Sci 92(5):1095–1111.
Pan B, Abel J, Ricci MS, Brems DN, Wang DIC, Trout BL (2006) Comparative oxidation studies of methionine residues reflect a structural effect of chemical kinetics in rhG-CSF. Biochemistry 45:15430–15443.
Yoshioka S, Aso Y, Izutsu K, Terao T (1994) Application of accelerated testing to shelf-life prediction of commercial protein preparations. J Pharm Sci 83(3):454–456.
Kerwin BA, Remmele RL (2007) Protect from light: photostability and protein biologics. J Pharm Sci 96(6):1468–1479.
Mizutani, T (1981) Estimation of protein and drug adsorption onto silicone-coated glass surfaces. J Pharm Sci 70(5):493–496.
Cohen S, Price C, Vlasak J (2007) β-Elimination and peptide bond hydrolysis: two distinct mechanisms of human IgG1 hinge fragmentation upon storage. JACS 129:6976–6977.
Cordoba AJ, Shyong B, Breen D, Harris RJ (2005) Non-enzymatic hinge region fragmentation of antibodies in solution. J Chrom B 818:115–121.
Werner R, Kopp K, Schlueter, M (2007) Glycosylation of therapeutic proteins in different production systems. Acta Paediatr Suppl 96(455):17–22.
Werne SJ, Creighton TE (1989) Effect of protein conformation on rate of deamidation: ribonuclease a. Proteins: Struct Funct Genet 5:8–12.
Tsai AM, Van Zanten JH, Betenbaugh MJ (1998) Study of protein aggregation due to heat denaturation: a structural approach using circular dichroism spectroscopy, nuclear magnetic resonance and static light scattering. Biotechnol Bioeng 59:273–280.
Kendrick BS, Cleland JL, Lam X, Nguyen T, Randolph TW, Manning MC, Carpenter JF (1998) Aggregation of recombinant human interferon gamma: kinetics and structural transitions. J Pharm Sci 87(9):1069–1076.
Chi EY,Krishnam S, Randolph TW, Carpenter JF (2003) Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 20(9):1325–1336.
Li S, Shöneich C, Borchardt, RT (1995) Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng 48:490–500.
Xie M, Schowen R, (1999) Secondary structure and protein deamidation. J Pharm Sci 88(1):8–13.
Luo D, Smith SW, Anderson BD (2005) Kinetics and mechanism of the reaction of cysteine and hydrogen peroxide in aqueous solution. J Pham Sci 94(2):304–316.
Cleland JL, Lam X, Kendrick B, Yang J, Yang T, Overcashier D, Brooks D, Hsu C, Carpenter J (2001) A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J Pharm Sci 90(3):310–321.
Constantino HR, Carrasquillo, KG, Cordero RA, Mumenthaler M, Hsu CC, Gribenow K (1998) Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone. J Pharm Sci 87(11):1412–1420.
Lai MC, Topp EM (1999) Solid-state chemical stability of proteins and peptides. J Pharm Sci 88(5):489–500.
Li S, Patapoff TW, Overcashier, D, Hsu C, Nguyen TH, Borchardt RT (1996) Effects of reducing sugars on the chemical stability of human relaxin in the lyophilized state. J Pharm Sci 85(8):873–877.
Kreilgaard L, Jones LS, Randolph TW, Frokjaer, Flink JM, Manning MC, Carpenter JF (1998) Effect of tween 20 on freeze–thawing- and agitation-induced aggregation of recombinant human factor XIII. J Pharm Sci 87(12):1597–1603.
Jones LS, Kaufmann A, Middaugh CR (2005) Silicon oil induced aggregation of proteins. J Pharm Sci 94(4):918–927.
PDA (Parenteral Drug Association) (2007) Technical report no. 39, Guidance for temperature-controlled medicinal products: maintaining the quality of temperature-sensitive medicinal products through the transportation environment.
The Gold Sheet, (September 2006) Global effort to control drug temperature in transit heats up. 40(9):1–19.
Martin SWH, Mo J (2007) Stability considerations for lyophilized biologics. Am Pharm Rev 10(4):31–36.
Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJA, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberge A, Cherney B (2008) Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J pharm sci (early view):1–5.
Fairweather WR, Mogg R, Bennett PS, Zhong J, Morrisey C, Schofield TL (2003) Monitoring the stability of human vaccines. J Biopharm Stat 13(3):395–413.
Schofield T, Apostol I, Koehler G, Powers S, Stawicki M, Wolfe R (2008) A rational approach to setting and maintaining specifications for biological and biotechnology-derived products. Biopharm International, (July 2008): 1–4.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Mazzeo, A., Carpenter, P. (2009). Stability Studies for Biologics. In: Huynh-Ba, K. (eds) Handbook of Stability Testing in Pharmaceutical Development. Springer, New York, NY. https://doi.org/10.1007/978-0-387-85627-8_17
Download citation
DOI: https://doi.org/10.1007/978-0-387-85627-8_17
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-85626-1
Online ISBN: 978-0-387-85627-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)